Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
about
Prophylactic human papillomavirus vaccinesBovine and human papillomaviruses: a comparative reviewPapillomavirus prophylactic vaccines: established successes, new approaches.Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretionsHuman papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.Characterization of a major neutralizing epitope on human papillomavirus type 16 L1Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of miceHuman papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccineProtective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.How will HPV vaccines affect cervical cancer?Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.A multimeric L2 vaccine for prevention of animal papillomavirus infections.Delivering on the promise: HPV vaccines and cervical cancer.In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyProgress in the development of a cervical cancer vaccine.Prophylactic HPV vaccines.Emerging human papillomavirus vaccines.Vaccination strategies for the prevention of cervical cancer.Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.Prevalence of human papilloma virus (HPV) and its genotypes in cervical specimens of Egyptian women by linear array HPV genotyping testNovel methods to treat and prevent human papillomavirus infection.
P2860
Q24545449-409DCA76-30B8-4B81-A5EC-4B496EF587BBQ26998701-2A31F6DF-79B5-4A74-801B-DCAFDA060FB8Q33614425-D9961144-C0B8-448A-AD2E-9F2F685C46FDQ33784891-5A40FEB8-EDA9-44A7-BED9-7C569952F9CFQ33785841-FEF32E96-668D-4BD1-B3BE-7734C2BB0897Q33813986-FFF638BA-EF17-4DC8-80CD-BBB38AFAE761Q33823755-79C067EB-51AA-4CCC-B110-15A7AB45A7FBQ33840918-A91CE7C7-D362-47DD-8636-754EB1CC61EDQ33853398-1AA6ED47-650F-4EA3-8631-8A78AC7CC1F7Q33908917-00C3047A-F0CF-4FD3-A0F6-5842C7854E27Q33932258-DAA29B12-3D07-40A7-8A54-FAB6F4F5A1A9Q34054427-40768991-4140-40C8-8E5E-2B12F540578EQ34069054-376A240C-5E89-4FD1-B16A-F49A62FA6148Q34075698-227240F1-9BDD-4ADA-9DA3-57BFA86205B9Q34078674-C87FE30A-8E38-431E-9E11-1EC42E41AC53Q34227402-DFD9F2BC-2BFF-4FAA-92DE-7AB26C104A58Q34341030-BDC7D984-7B39-4484-9D9B-99873C183352Q34343006-50AF5860-F895-4BF5-8EEE-D89230DCFE31Q34347179-8BC47FA8-81C2-45CF-9728-E9C654FC7200Q34434903-22DCF93E-5BE2-4505-87DE-5339F212C1C5Q34483573-33234BAA-EBAD-4312-BE32-B8C021B76275Q34786808-49487E6F-D459-46F3-8040-4F8985562E95Q35185992-0FD27852-83ED-47C3-A428-E6BF35A11928Q35235035-185C2B81-6110-468B-99A7-F187BE196B3AQ35552591-B33680EA-0798-4EC6-8A8F-72484B99F086Q35553171-00D66F20-1479-437A-8628-F19F8CB5EA1FQ35566274-3E137EFE-881B-4D46-BFE9-DA96093E5DEBQ35607053-11CB0564-91A0-4C65-BBEB-880371F1A4D1Q35697573-6119A38A-CA5F-4A18-B415-5144CE457487Q35867810-AC3267D4-CB55-46E9-BCC7-25DAE7FA9B91Q35890718-CCDA74E0-C6A0-43A3-BA5C-DD7854283B89Q35891225-A967E512-09D8-4E9A-B61D-5C93911557FFQ35918842-A35638B8-04B8-413D-9848-D7CD2DA11BDAQ35919119-6E21681D-8977-4D2C-9DF9-F678F36D575DQ35984558-A17FCBE2-51CA-4BB9-9E9C-89D881A31C5EQ36066004-90F5BBDD-F6C9-49BA-9F71-05ACC46D30CBQ36066161-A2C6C4CA-88C1-4727-8300-6D6B6F198D7EQ36088309-39F84FF2-2220-4377-B90B-0EB97C8CF8EBQ36587825-0CB95D1F-35FA-4FE3-88D2-DA3DD9236449Q36607397-5C3018AD-5755-4147-949A-3B92354E93D1
P2860
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Virus-like particles of bovine ...... and therapeutic immunization.
@en
type
label
Virus-like particles of bovine ...... and therapeutic immunization.
@en
prefLabel
Virus-like particles of bovine ...... and therapeutic immunization.
@en
P2093
P356
P1433
P1476
Virus-like particles of bovine ...... and therapeutic immunization.
@en
P2093
Armstrong A
Chandrachud LM
Grindlay GJ
Kirnbauer R
McGarvie GM
Schiller JT
P356
10.1006/VIRO.1996.0220
P407
P577
1996-05-01T00:00:00Z